Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | TSPO | P30536 | 1/20 | 0.84 |
| ▸ | BRD2 | P25440 | 5/20 | 0.71 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.69 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | BRD1 | O95696 | 1/20 | 0.69 |
| ▸ | CCL2 | P13500 | 1/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.69 |
| ▸ | EP300 | Q09472 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23348657 | 1.00 | BRD4 (0.84) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL23320675 | 0.99 | BRD4 (0.83) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL23348599 | 0.92 | BRD4 (0.83) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL19465691 | 0.92 | BRD4 (1.00) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL12228301 | 0.92 | BRD4 (1.00) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL17051091 | 0.92 | BRD4 (1.00) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL23320757 | 0.92 | BRD4 (0.74) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL17854812 | 0.91 | BRD4 (0.86) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL23320674 | 0.91 | BRD4 (0.82) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL23321411 | 0.91 | BRD4 (0.82) | BRD4ADORA3TSPOBRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | BRD4 2/4885ADORA3 4629/4885TSPO 2710/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | BRD4 2/4885ADORA3 4656/4885TSPO 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.